A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients

PHASE1RecruitingINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions

Atopic DermatitisHidradenitis Suppurativa (HS)Rheumatoid Arthritis (RA)

Interventions

DRUG

QLS12010

QLS12010 oral capsule(s)

DRUG

Placebo

Matching placebo oral capsule(s)

Trial Locations (1)

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

Shanghai Qilu Pharmaceutical Research and Development Center LTD

INDUSTRY